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Background: Recently, the triglyceride glucose (TyG) index has been considered a surrogate marker of insulin resistance which is a 
well-known pathogenic factor in nonalcoholic fatty liver disease (NAFLD). However, few studies have investigated the relationship 
between the TyG index and NAFLD. Thus, we investigated the relationship between the TyG index and NAFLD and the effective-
ness of the TyG index compared with the homeostasis model assessment of insulin resistance (HOMA-IR) in identifying NAFLD in 
Korean adults.
Methods: Participants of 4,986 who underwent ultrasonography in a health promotion center were enrolled. The TyG index was cal-
culated as ln [fasting triglycerides (mg/dL)×fasting glucose (mg/dL)/2], and HOMA-IR was estimated. NAFLD was diagnosed by 
ultrasonography.
Results: Significant differences were observed in metabolic parameters among the quartiles of the TyG index. The prevalence of 
NAFLD significantly increased with increment in the TyG index. After adjusting for multiple risk factors, a logistic regression analy-
sis was performed. When the highest and lowest quartiles of the TyG index and HOMA-IR were compared, the odds ratios for the 
prevalence of NAFLD were 2.94 and 1.93 (95% confidence interval, 2.32 to 3.72 and 1.43 to 2.61; both P for trend <0.01), respec-
tively. According to the receiver operating characteristic analysis, the TyG index was superior to HOMA-IR in predicting NAFLD.
Conclusion: The TyG index and prevalence of NAFLD were significantly related and the TyG index was superior to HOMA-IR in 
predicting NAFLD in Korean adults.
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is one of the most 
frequently occurring disorders of the liver, with the incidence 
gradually increasing worldwide [1,2]. NAFLD encompasses a 
range of liver diseases, including liver fibrosis, simple steatosis 
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and cirrhosis. Histopathologic changes associated with NAFLD 
may lead to liver failure, hepatocellular carcinoma and ultimate-
ly, hepatic mortality [3,4]. In recent years, the importance of 
NAFLD as a metabolic disorder has been realized, not only 
with regards to hepatic manifestation, but several studies have 
shown that NAFLD is also related to type 2 diabetes mellitus, 
abdominal obesity, dyslipidemia, hypertension, and cardiovas-
cular disease [5-9]. Although the mechanisms associated with 
the onset of NAFLD remain poorly understood, insulin resis-
tance (IR) has been found to be associated with the develop-
ment of NAFLD [10-12]. The homeostasis model assessment of 
insulin resistance (HOMA-IR) is a widely used surrogate mark-
er of IR and is one of several methods used for evaluating IR 
[13]. Numerous studies have found that an independent rela-
tionship exists between NAFLD and HOMA-IR [14-16]. In ad-
dition, other studies have proposed that HOMA-IR diagnostic 
criteria can be used for predicting NAFLD [17,18].
Recently, the triglyceride glucose (TyG) index, which is cal-
culated on the basis of triglycerides (TGs) and fasting glucose 
levels, has emerged as a reliable surrogate marker of IR. More-
over, the TyG index correlates with the HOMA-IR and hyperin-
sulinemic-euglycemic clamp test for recognizing IR [19-21]. 
Despite this, few studies have evaluated the TyG index in the 
context of NAFLD [22-24]. Therefore, in this study, we sought 
to elucidate the relationship between NAFLD and the TyG in-
dex and compare the effectiveness of the TyG index and 
HOMA-IR in identifying NAFLD in Korean adults.
METHODS
Study participants
A total of 5,989 Korean subjects (age ≥20 years) who were par-
ticipants in an in-depth health checkup program at the Gangnam 
Severance Hospital Health Promotion Center from January 
2008 to February 2015, were included in the study. Subjects 
with elevated levels of TGs (≥400 mg/dL), an acute inflamma-
tion, history of malignancy, renal or infectious disease, viral 
hepatitis (positive for hepatitis B surface antigen or anti-hepati-
tis C virus antibody), liver cirrhosis or malignancy observed via 
ultrasound were excluded from this study. Subjects with history 
of diabetes mellitus or newly diagnosed diabetes in this exam 
were also excluded. Furthermore, any subjects taking statins, 
TG-reducing therapies (e.g., fenofibrate or omega-3), thiazoli-
dinediones, or injecting insulin were also excluded, as were 
males and females with a history of heavy alcohol consumption 
that exceeded 30 and 20 g/day, respectively. After the exclusion 
criteria were applied, 4,986 participants were included in the fi-
nal analysis. All methods were performed in accordance with 
the ethical standards of the responsible committee on human 
experimentation and with the World Medical Association Dec-
laration of Helsinki. Written informed consents were provided 
by all subjects before data collection. The study protocol was 
approved by the Institutional Review Board of Yonsei Universi-
ty College of Medicine (approval number: 2018-0077).
Clinical characteristics of the study participants
The height and weight of each participant was measured and the 
body mass index (BMI, kg/m2) was calculated. The social and 
medical history of each participant was obtained by administer-
ing a self-questionnaire, which included questions regarding 
smoking, alcohol status, medications, and a history of other dis-
eases. Experienced technicians measured the systolic blood pres-
sure (SBP) and diastolic blood pressure (DBP) respectively, af-
ter a 5-minute of rest, with the patient’s arm placed at the same 
level as the heart using an automated blood pressure monitor 
(HEM-7080IC, Omron Healthcare, Lake Forest, IL, USA). A di-
agnosis of diabetes mellitus was made on the basis of a prior his-
tory of diabetes or the American Diabetes Association’s diagnos-
tic standards. Subjects with SBP and/or DBP ≥140/90 mm Hg 
or those presently using antihypertensive medication were de-
fined as having hypertension. Subjects who had regularly 
smoked cigarettes over the past 6 months were considered to be 
current smokers.
Biochemical parameters
After an 8-hour fasting period, blood samples were collected 
from all subjects. The samples were immediately centrifuged 
and the serum was subsequently stored at –70°C until further 
analysis was required. The levels of fasting plasma glucose 
(FPG), total cholesterol (TC), high density lipoprotein choles-
terol (HDL-C), TG, aspartate aminotransferase (AST), and ala-
nine aminotransferase (ALT) were assessed using enzymatic 
procedures, with an automated chemistry analyzer (Hitachi 
7600-120, Hitachi, Tokyo, Japan). The level of low density lipo-
protein cholesterol (LDL-C) was calculated using Friedewald 
formula. The TyG index was computed using the following for-
mula: ln [fasting TGs (mg/dL)×fasting glucose (mg/dL)/2] 
[19]. The levels of hepatitis B surface antigen and anti-hepatitis 
C virus antibodies were measured using a Roche E-170 device 
(Roche Diagnostics, Mannheim, Germany). The fasting serum 
insulin level was determined using a radioimmunoassay kit 
(Daiichi Radioisotope Labs, Tokyo, Japan). IR was approximat-
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ed using the HOMA-IR index which was calculated using fol-
lowing formula: [fasting insulin (μU/mL)×FPG (mg/dL)/405].
Ultrasonographic analyses
A diagnosis of fatty liver disease was made on the basis of the 
findings of an abdominal ultrasonography scan performed using 
a 3.5-MHz transducer (HDI 5000, Philips, Bothell, WA, USA). 
One of three experienced radiologists, who were blinded to the 
subjects’ clinical information, performed the abdominal ultraso-
nographic examination. Any degree of fat accumulation in the 
liver was considered to be NAFLD in the present study. The 
subjects were classified into four groups on the basis of the ex-
istence and severity of NAFLD according to the level of hepatic 
tissue hyperechogenicity, discrepancy between the liver and 
right kidney, and visibility of the vascular structures [25].
Statistical analysis
Continuous variables with a normal distribution were presented 
as the mean±standard deviation. Continuous variables with 
skewed distributions were presented as the median with the in-
terquartile range and were transformed to a log scale for analysis. 
Intergroup comparisons were performed using Student’s t test or 
one-way analysis of variance with post hoc analysis. Categorical 
variables with percentages were compared using chi-square test. 
After adjusting for any confounding variables, a multivariate lo-
gistic regression analysis was used for estimating the odds ratio 
(OR) and associated 95% confidence interval (CI) for NAFLD 
on the basis of the TyG index and HOMA-IR. The area under the 
curve (AUC) of the receiver operating characteristic (ROC) 
curve was calculated for comparing the predictive power of the 
TyG index and HOMA-IR for the prevalence of NAFLD. Z test 
was used for comparing the differences between AUCs. Statisti-
cal significance was considered for P values less than 0.05. SPSS 
for Windows version 23.0 (IBM Co., Armonk, NY, USA) and 
MedCalc (MedCalc software, Olstead, Belgium) were used for 
performing all statistical analyses in the present study. 
RESULTS
A total of 4,986 subjects were included in the present study, 
2,069 of whom were diagnosed with NAFLD using ultrasound 
data (41.5%). The comparison of the baseline characteristics of 
the subjects enrolled in this study, with and without NAFLD, is 
presented in Table 1. The subjects with NAFLD were older; 
Table 1. Clinical Characteristics of the Study Subjects Based on NAFLD Status
Characteristic All (n=4,986) No NAFLD (n=2,917) NAFLDa (n=2,069)
Age, yr 52.63±9.26 52.29±9.70 53.11±8.58
Sex, male/female 2,979/2,007 1,422/1,495 1,557/512
BMI, kg/m2 23.82±3.17 22.57±2.74 25.59±2.87
SBP, mm Hg 124.97±16.55 121.91±16.51 129.28±15.61
DBP, mm Hg 77.91±10.20 75.78±10.11 80.90±9.55
FPG, mg/dL 93.93±10.70 91.73±10.50 97.04±10.19
TC, mg/dL 194.65±34.97 191.88±34.00 198.56±35.94
TG, mg/dL 96 (69–139) 83 (61–114) 120 (87–168)
HDL-C, mg/dL 50.20±12.75 53.17±13.19 46.02±10.79
LDL-C, mg/dL 120.21±31.21 116.64±30.09 125.24±32.07
AST, IU/L 23.29±9.39 22.03±8.44 25.05±10.33
ALT, IU/L 24.60±16.03 20.82±12.59 29.93±18.64
TyG index 8.44±0.54 8.28±0.51 8.67±0.50
Insulin, µIU/mL 4.4 (3.0–6.5) 3.8 (2.6–5.5) 5.3 (3.6–7.6)
HOMA-IR 1.03 (0.67–1.56) 0.87 (0.57–1.29) 1.27 (0.85–1.83)
Hypertension 1,003 (20.1) 468 (16.0) 535 (25.9)
Values are expressed as mean±SD, median (interquartile range), or number (%). 
NAFLD, nonalcoholic fatty liver disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glu-
cose; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; AST, aspartate ami-
notransferase; ALT, alanine aminotransferase; TyG, triglyceride glucose; HOMA-IR, homeostasis model assessment of assessment of insulin resistance.
aIntergroup comparison using Student’s t test, all P<0.01.
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more likely to be male; and had a higher BMI, blood pressure, 
insulin, HOMA-IR, LDL-C, FPG, TC, TG, AST, ALT, and TyG 
index but lower HDL-C than the subjects without NAFLD. In 
addition, the proportion of subjects with hypertension was sig-
nificantly higher among those with NAFLD than those without.
The subjects were divided into four groups on the basis of 
their TyG indices (Q1: TyG index ≤8.04; Q2: 8.05≤ TyG index 
≤8.42; Q3: 8.43≤ TyG index ≤8.81; Q4: TyG index ≥8.82). 
Table 2 outlines the demographic, clinical, and laboratory infor-
mation for each group. The metabolic parameters were associat-
ed with significant differences between the groups. There was 
an increase in the number of males, BMI, SBP, DBP, AST, ALT, 
insulin, HOMA-IR, FPG levels, the prevalence of hypertension, 
as well as an increase in the levels of TC, TG, and LDL-C. 
However, the level of HDL-C was found to decrease with in-
creasing TyG index.
The subjects were also classified into four groups according 
to their HOMA-IR (Q1: HOMA-IR ≤0.67; Q2: 0.68≤ HOMA-
IR ≤1.03; Q3: 1.04≤ HOMA-IR ≤1.56; Q4: TyG index ≥1.57) 
and results demonstrated that both the prevalence and severity 
of NAFLD increased with increasing TyG index and HOMA-IR 
quartiles (Fig. 1).
The association between the TyG index and NAFLD was in-
vestigated by dividing the TyG index into the following quar-
tiles: the first quartile (Q1) was used as a reference (Table 3). 
When Q1 was set as a reference, the unadjusted multivariate lo-
gistic regression analysis revealed that in all subjects, the TyG 
indices for Q2, Q3, and Q4 were associated with higher OR for 
the presence of NAFLD. Moreover, these relationships re-
mained significant (P for trend <0.01) even after adjusting for 
confounding variables. The association between the HOMA-IR 
and the presence of NAFLD was further investigated by catego-
rizing the HOMA-IR into quartiles, with the first quartile used 
as the reference (Table 3). Results showed that there was a sig-
nificant relationship (P for trend <0.01) between the higher 
HOMA-IR quartile and the presence of NAFLD, even after ad-
justing for confounding variables. After adjusting for multiple 
risk factors, the OR (95% CI) in the highest quartile for NAFLD 
using HOMA-IR was 1.93 (95% CI, 1.43 to 2.61) compared 
with 2.94 (95% CI, 2.32 to 3.72) for the TyG index. The AUC 
(95% CI) of the ROC curve for the TyG index at 0.716 (95% CI, 
0.702 to 0.731) was significantly higher than that of the HOMA-
Table 2. Clinical Characteristics of the Study Participants Based on TyG Index
Characteristic Q1 (n=1,249) Q2 (n=1,246) Q3 (n=1,245) Q4 (n=1,246)a
Age, yr 51.13±9.98 53.48±9.26b 53.64±8.83c 52.30±8.70d,e,f 
Sex, male/female 475/774 672/574 842/403 990/256
BMI, kg/m2 22.40±2.94 23.49±3.15b 24.20±2.98c,g 25.19±2.92d,e,f
SBP, mm Hg 119.77±16.00 123.87±16.69b 127.44±16.00c,g 128.80±16.01d,e
DBP, mm Hg 74.20±10.03 77.06±10.02b 79.58±9.72c,g 80.80±9.76d,e,f
FPG, mg/dL 86.81±9.31 93.13±9.34b 96.56±9.90c,g 99.26±9.98d,e,f
TC, mg/dL 184.80±33.25 193.23±33.76b 195.88±35.10c 204.72±34.87d,e,f
TG, mg/dL 55 (48–63) 82 (74–90)b 113 (102–126)c,g 185 (157–230)d,e,f
HDL-C, mg/dL 58.52±13.14 52.43±12.05b 47.28±10.62c,g 42.56±8.86d,e,f
LDL-C, mg/dL 110.46±29.59 121.46±30.20b 124.39±31.31c 124.57±31.59d
AST, IU/L 21.94±8.40 22.62±9.56 23.30±9.49c 25.29±9.78d,e,f
ALT, IU/L 19.72±11.17 22.80±16.25b 25.23±15.29c,g 30.67±18.49d,e,f
TyG index 7.76±0.21 8.24±0.11b 8.60±0.11c,g 9.16±0.26d,e,f
Insulin, µIU/mL 3.0 (2.2–4.6) 4.1 (2.9–5.9)b 4.7 (3.5–6.7)c,g 5.7 (3.9–8.0)d,e,f
HOMA-IR 0.65 (0.45–0.99) 0.93 (0.66–1.34)b 1.11 (0.79–1.62)c,g 1.40 (0.29–1.93)d,e,f
Hypertension 164 (13.1) 232 (18.6) 287 (23.1) 320 (25.7)
Values are expressed as mean±SD, median (interquartile range), or number (%). 
TyG, triglyceride glucose; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TC, total 
cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; HOMA-IR, homeostasis model assessment of insulin resistance.
aIntergroup comparisons using one-way analysis of variance, all P<0.01; bP<0.05 between Q1 and Q2; cP<0.05 between Q1 and Q3; dP<0.05 between 
Q1 and Q4; eP<0.05 between Q2 and Q4; fP<0.05 between Q3 and Q4; gP<0.05 between Q2 and Q3.
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IR at 0.672 (95% CI, 0.650 to 0.694) (P<0.01). These results 
suggest that regarding the prediction of NAFLD, the TyG index 
is superior to the HOMA-IR.
DISCUSSION
In the present study, following adjustment for conventional risk 
factors, an independent relationship between the TyG index and 
NAFLD was observed. Furthermore, results demonstrated that 
the TyG index was superior in its ability to identify NAFLD 
compared with HOMA-IR. To the best of our knowledge, this is 
the first study wherein the diagnostic effectiveness of the TyG 
index and HOMA-IR for identifying NAFLD has been com-
pared.
NAFLD is related to IR and metabolic syndromes associated 
with hyperinsulinemia, hypertriglyceridemia, and hyperglyce-
Table 3. Nonalcoholic Fatty Liver Disease OR and 95% CI Based on the TyG Index and HOMA-IR Quartiles
OR (95% CI)
Q1 Q2 Q3 Q4a
TyG index
   Unadjusted 1.00 2.35 (1.95–2.83) 4.57 (3.81–5.49) 8.73 (7.25–10.52)
   Multivariable adjustedb 1.00 1.57 (1.26–1.94) 2.32 (1.87–2.88) 2.94 (2.32–3.72)
HOMA-IR
   Unadjusted 1.00 1.88 (1.46–2.42) 2.93 (2.28–3.76) 5.15 (3.98–6.66)
   Multivariable adjustedb 1.00 1.29 (0.97–1.71) 1.53 (1.15–2.03) 1.93 (1.43–2.61)
OR, odds ratio; CI, confidence interval; TyG, triglyceride glucose; HOMA-IR, homeostasis model assessment of insulin resistance.
aAll P for trends <0.01 in multivariate logistic regression analysis; bAdjusted for age, sex, body mass index, systolic blood pressure, total cholesterol, 


























Severity of fatty liver:  Normal  Mild  Moderate  Severe
HOMA-IR
 Q1 Q2 Q3 Q4  Q1 Q2 Q3 Q4
 1.0 2.5 4.7 9.3  1.0 3.4 7.4 12.2Severe Severe
 4.5 9.7 17.4 26.8  10.2 13.9 18.3 26.8Moderate Moderate
 12.2 21.3 27.7 29.0  16.8 25.1 26.4 27.2Mild Mild
 82.3 66.5 50.2 34.9  72.0 57.6 47.9 33.8Normal Normal
Fig. 1. The prevalence and severity of nonalcoholic fatty liver disease (NAFLD) based on the (A) triglyceride glucose (TyG) index and (B) 
homeostasis model assessment of insulin resistance (HOMA-IR). Ultrasonography was used for diagnosing the severity of fatty liver dis-
ease (all P<0.01). 
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mia [5,26-28]. Recently, Zheng et al. [29], even demonstrated 
that TyG index could predict an incidence of NAFLD in longi-
tudinal, prospective cohort study. In agreement with previous 
studies, most of the metabolic risk factors evaluated by us in-
creased or decreased according to the TyG index and the pres-
ence of NAFLD. In addition, unlike previous studies, which re-
ported an association between the presence of NAFLD and the 
TyG index [22-24], we further examined the relationship be-
tween the severity of NAFLD and the TyG index. Results dem-
onstrated that the severity of NAFLD was strongly associated 
with the TyG index.
IR has been shown to have an important pathological associa-
tion with NAFLD. Furthermore, both the TyG index and 
HOMA-IR are well-known representative markers of IR. In the 
present study, Pearson’s correlation analysis was performed and 
confirmed that there was a significant relationship between the 
TyG index and HOMA-IR (r=0.466, P<0.001) (data not 
shown). Interestingly, we observed that the TyG index displayed 
a higher OR and AUC of the ROC curve than the HOMA-IR 
for predicting NAFLD. These results suggest that the TyG index 
is a superior surrogate marker for predicting NAFLD. Recent 
studies have also reported the superiority of the TyG index for 
identifying IR [21,30,31]. For example, Vasques et al. [21] re-
ported that the TyG index was superior to HOMA-IR in identi-
fying IR in a Brazilian population. Although the reason for this 
finding remains unknown, the underlying mechanism for the 
superiority of the TyG index over HOMA-IR in predicting 
NAFLD can be explained by the crucial roles of glucotoxicity 
and lipotoxicity play in the modulation of IR, which shows key 
pathological association with NAFLD [32-34]. Our findings are 
in line with those of recent studies that demonstrate the superi-
ority of the TyG index to HOMA-IR for evaluating metabolic 
risk factors associated with IR (e.g., diabetes and subclinical 
atherosclerosis) [35-37]. In contrast, other studies have reported 
that the HOMA-IR primarily reflects IR in the liver [38,39]. The 
mechanisms associated with this relationship should be clarified 
in prospective large-scale studies.
The present study had the following limitations. (1) Since this 
was a cross-sectional observational study, a causality cannot be 
presumed from the results. (2) The participants comprised Ko-
rean adults from a single institution and most of subjects were 
non-obese, healthy population. For these reasons, levels of fast-
ing insulin and HOMA-IR were relatively low compared with 
other previous studies. Thus, the generalizability of the results 
may be limited. (3) The TyG index was compared with the 
HOMA-IR rather than with the hyperinsulinemic-euglycemic 
clamp test as the gold standard for assessing IR. However, the 
IR index derived from a euglycemic clamp has been shown to 
correlate with the TyG index and HOMA-IR. (4) A liver biopsy 
with a histological examination was not performed, which is the 
gold standard technique for identifying steatosis. Moreover, ul-
trasound was used for assessing the presence of NAFLD in this 
study; however, ultrasonography, a first-line imaging technique, 
is a highly useful noninvasive technique that is often used in 
both clinical practice and epidemiological studies [40].
 The results of the present study indicate that there is a signifi-
cant association between the TyG index and the prevalence of 
NAFLD in Korean subjects. Moreover, the TyG index was su-
perior to HOMA-IR in predicting NAFLD. The TyG index is a 
simple and cost-effective marker of IR and appears to be a use-
ful marker for predicting NAFLD. 
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